FDA Multiple Myeloma Approval Gives Fresh Catalyst To Johnson & Johnson

The FDA approved a new DARZALEX FASPRO combination therapy for newly diagnosed multiple myeloma patients who are not eligible for stem cell transplant. The decision expands DARZALEX FASPRO’s indications and reinforces its role as a foundational treatment option in multiple myeloma care. This regulatory milestone is material for Johnson & Johnson, affecting treatment choices, its pharmaceutical pipeline, and potential revenue streams. For Johnson & Johnson (NYSE:JNJ), this approval adds...